Bavitux Redux: If it Looks Too Good to be True, it Probably Is
Article
Just last week I reviewed the favorable results in a randomized phase II clinical trial with the novel vascular-targeting immunotherapy bavituximab, which was associated with an approximate doubling of median overall survival when added to Taxotere (docetaxel) and compared with Taxotere alone, along with a much more modest improvement in response rate and progression-free survival.